TET2 and leukemia: I predict that ascorbate administration will benefit ascorbate-deficient individuals with clonal hematopoiesis, not by changing clonal competition but by preventing a TET-deficient state that collaborates with clonal hematopoiesis mutations (in TET2 or other genes) to cause leukemia or exacerbate inflammation.